Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.1%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Free Report)’s share price traded up 3.1% during trading on Friday . The company traded as high as $19.86 and last traded at $19.86. 4,603 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 1,089,561 shares. The stock had previously closed at $19.27.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SNDX. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $34.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. Scotiabank cut Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 14th. Stifel Nicolaus raised their price objective on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

View Our Latest Stock Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

The company has a 50 day simple moving average of $20.62 and a 200-day simple moving average of $21.35. The stock has a market cap of $1.70 billion, a P/E ratio of -5.98 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.11. During the same period in the prior year, the company posted ($0.59) earnings per share. As a group, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan bought 1,250 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average price of $20.03 per share, for a total transaction of $25,037.50. Following the transaction, the chief financial officer now directly owns 52,623 shares in the company, valued at $1,054,038.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SNDX. CWM LLC boosted its stake in shares of Syndax Pharmaceuticals by 415.3% during the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares in the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at approximately $37,000. Quadrant Capital Group LLC grew its holdings in shares of Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after acquiring an additional 1,496 shares during the period. Annandale Capital LLC purchased a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $67,000. Finally, Signaturefd LLC raised its position in shares of Syndax Pharmaceuticals by 2,874.6% in the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after acquiring an additional 3,622 shares in the last quarter.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Read More

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.